Search: WFRF:(Poromaa Inger Sundström) >
Effect of sibutrami...
Effect of sibutramine on weight reduction in women with polycystic ovary syndrome : a randomized, double-blind, placebo-controlled trial
-
- Lindholm, Åsa (author)
- Uppsala universitet,Institutionen för kvinnors och barns hälsa
-
- Bixo, Marie (author)
- Umeå universitet,Obstetrik och gynekologi
-
- Björn, Inger (author)
- Umeå universitet,Obstetrik och gynekologi
-
show more...
-
- Wölner-Hanssen, Pål (author)
- Lund University,Lunds universitet,Obstetrik och gynekologi, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Obstetrics and Gynaecology (Lund),Section V,Department of Clinical Sciences, Lund,Faculty of Medicine
-
- Eliasson, Mats (author)
- Umeå universitet,Medicin
-
- Larsson, Anders (author)
- Uppsala universitet,Klinisk kemi
-
- Johnson, Owe (author)
- Umeå universitet,Medicin
-
- Sundström Poromaa, Inger (author)
- Uppsala universitet,Institutionen för kvinnors och barns hälsa,Klinisk och experimentell reproduktionsbiologi/ Olovsson
-
show less...
-
(creator_code:org_t)
- Elsevier BV, 2008
- 2008
- English.
-
In: Fertility and Sterility. - : Elsevier BV. - 0015-0282 .- 1556-5653. ; 89:5, s. 1221-1228
- Related links:
-
http://www.ncbi.nlm....
-
show more...
-
http://dx.doi.org/10...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
https://lup.lub.lu.s...
-
show less...
Abstract
Subject headings
Close
- OBJECTIVE: To examine the efficacy of sibutramine together with brief lifestyle modification for weight reduction in obese women with polycystic ovary syndrome (PCOS). DESIGN: Investigator-initiated, multicenter, double-blind, randomized, parallel-group clinical trial. SETTING: Departments of Obstetrics and Gynecology in primary care, referral centers, and private practice. PATIENT(S): Forty-two patients with confirmed PCOS were included in the study, and 34 patients completed the study. INTERVENTION: Sibutramine 15 mg once daily together with brief lifestyle modification was compare with placebo together with brief lifestyle modification. MAIN OUTCOME MEASURE(S): The primary endpoint was to assess weight loss. Secondary endpoints included the efficacy of sibutramine for treatment of menstrual pattern and cardiovascular risk factors. RESULT(S): After 6 months the sibutramine group had lost 7.8 +/- 5.1 kg compared with a weight loss of 2.8 +/- 6.2 kg in the placebo group. Sibutramine treatment resulted in significant decreases in apolipoprotein B, apolipoprotein B/apolipoprotein A ratio, triglycerides, and cystatin C levels. CONCLUSION(S): Sibutramine in combination with lifestyle intervention results in significant weight reduction in obese patients with PCOS. In addition to the weight loss, sibutramine seems to have beneficial effects on metabolic and cardiovascular risk factors.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Reproduktionsmedicin och gynekologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Obstetrics, Gynaecology and Reproductive Medicine (hsv//eng)
Keyword
- Polycystic ovary syndrome
- sibutramine
- randomized clinical trial
- obesity
- MEDICINE
- MEDICIN
- randomized clinical trial
- polycystic ovary syndrome
- sibutramine
- obesity
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database